الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 166 |  |  |
| | | from | 166 | | |
Abstract
It is estimated that approximately 120-130 million
individuals, i.e. 3% of the world population, are chronically
infected with HCV. Egypt has the highest worldwide The current study included 85 Egyptian hepatitis C patients 31
females (36.5%) and 54 males (63.5%). All patients in the study
signed written informed consent. They aged between 18 to 60 years
with mild changes in the liver biopsy and with more than portal
fibrosis. Patients with compensated cirrhosis (Child A) were
included if there were no varices. All of the patients fulfilled the
inclusion criteria applied by viral hepatitis of Egyptian Ministry of
Health, Egypt.
The study protocol was approved by the Ethical Review
Committee (ERC) of Faculty of Medicine ,University of Benha and
by National Committee for control of viral hepatitis of Egyptian
Ministry of Health, Egypt.
from 85 patients, 74 patients responded to standard therapy,
i.e. had a sustained virological response after 12 weeks of treatment
(SVR12), while 11 patients (9 males and 2 females) did not respond
to the therapy (non-SVR).The study investigated the possible effect of the following on
the treatment response: HLA class II alleles (DRB1*13,
DRB1*07and DQB1*02), IL-10 level before starting the treatment,
liver histopathological status by liver biopsy assessment, body mass
index (BMI), presence of antischistosoma antibodies and some
laboratory parameters including AST, ALT, total bilirubin, blood
glucose, TSH, AFP, WBCs count, Hb, blood platelets count and
creatinine. Blood samples were drawn at baseline from the beginning of the treatment. Baseline characteristics of subjects included clinical
history, physical examination, body mass index (BMI) were taken.